Among all KRAS mutations in NSCLC, the most prevalent is the single-nucleotide variant p.G12C, which results in a glycine-to-cysteine substitution at codon 12 in exon 2 and accounts for approximately 40% of KRAS mutations, with an overall prevalence of about 13% in lung adenocarcinoma [7,8,9,10]. Here, KRAS is linked to lung adenocarcinoma.